Key facts
- Ossium Health’s last known valuation is $325.0M (Jul 2023).
- It has raised $125.8M across 1 recorded rounds; the latest was Early Stage VC ($10.4M) in May 2018.
- Notable investors include Alumni Ventures, General Catalyst, Gaingels, Village Global, First Round Capital — 30 tracked in total.
- Ossium Health has filed 1 Form D with the SEC, most recently May 2018 ($10.4M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Ossium Health
Funding rounds
1 roundsAbout Ossium Health
Developer of stem cell-based therapies designed to improve the health, vitality, and longevity of human beings through bioengineering. The company's therapies cure leukemia and other blood diseases, improve organ transplantation, treat radiation poisoning, and heal tissue damage, enabling healthcare professionals to improve a new paradigm for cell therapy development by bringing the deceased donor transplant ecosystem into the fight against diseases of the blood and immune systems.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2016
- Employees
- 92
- Website
- ossiumhealth.com/
- Ownership
- Privately Held (backing)
Ossium Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ossium Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ossium Health in its N-PORT filings yet. We sweep new filings monthly.